|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61P 19/08 | |
| A61K 38/18 | |||
| A61K 38/17 | |||
| A61P 21/00 | |||
| A61P 19/10 | |||
| A61K 31/663 | |||
| C07K 14/705 |
| (11) | Number of the document | 2475427 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10816109.2 |
| Date of filing the European patent application | 2010-09-09 | |
| (97) | Date of publication of the European application | 2012-07-18 |
| (45) | Date of publication and mention of the grant of the patent | 2016-11-30 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2010/048322 |
| Date | 2010-09-09 |
| (87) | Number | WO 2011/031901 |
| Date | 2011-03-17 |
| (30) | Number | Date | Country code |
| 276287 P | 2009-09-09 | US |
| (72) |
SEEHRA, Jasbir, US
KNOPF, John, US
ATTIE, Ken, US
|
| (73) |
Acceleron Pharma, Inc.,
128 Sidney Street, Cambridge, MA 02139,
US
|
| (54) | ACTRIIB ANTAGONISTS AND DOSING AND USES THEREOF |
| ACTRIIB ANTAGONISTS AND DOSING AND USES THEREOF |